Real-world attrition rates after second-line therapy or later in patients from the flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
relapsed/refractory multiple myeloma relapsed/refractory,multiple myeloma,lenalidomide,second-line second-line therapy,attrition rates,real-world
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要